mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option

Bibliography

• Alexandrescu DT, Dasanu CA. Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother 2006;7(18):2481-9
   PubMed Web of Science ®Google Scholar
• Radulovic S, Bjelogrlic SK. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON 2007;12(Suppl 1):S151-62
   PubMed Web of Science ®Google Scholar
• Hutson TE, Figlin RA. Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park) 2007;21(10):1175-80
   PubMed Web of Science ®Google Scholar
• Smith SM. Clinical development of mTOR inhibitors: a focus on lymphoma. Rev Recent Clin Trials 2007;2(2):103-10
   PubMedGoogle Scholar
• Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008;7(6):1347-54
   PubMed Web of Science ®Google Scholar
• Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006;17(5):487-94
   PubMed Web of Science ®Google Scholar
• Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-61
   PubMed Web of Science ®Google Scholar
• Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007;82(4):381-8
   PubMed Web of Science ®Google Scholar
• Rao RD, Buckner JC, Sarkaria JN. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 2004;4(8):621-35
   PubMed Web of Science ®Google Scholar
• Reddy GK, Mughal TI, Rini BI. Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma. Clin Genitourin Cancer 2006;5(2):110-3
   PubMed Web of Science ®Google Scholar
• Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002;3(2):295-304
   PubMedGoogle Scholar
• Shor B, Zhang WG, Toral-Barza L, et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008;68(8):2934-43
   PubMed Web of Science ®Google Scholar
• Seeliger H, Guba M, Kleespies A, et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007;26(3-4):611-21
   PubMed Web of Science ®Google Scholar
• Metcalf CA III, Bohacek R, Rozamus LW, et al. Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for antitumor therapy. Proc Am Assoc Cancer Res 2004;45:2476
   Google Scholar
• US National Institutes of Health database of clinical trials. Available from: www.clinicaltrials.gov
   Google Scholar
• Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22(12):2336-47
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271
   PubMed Web of Science ®Google Scholar
• Wood L, Bukowski RM, Dreicer R, et al. Temsirolimus in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients previously treated with VEGF-targeted therapy [abstract 16067]. J Clin Oncol 2008;26
   PubMedGoogle Scholar
• Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19(8):1387-92
   PubMed Web of Science ®Google Scholar
• UpToDate, Inc. Temsirolimus drug information. Available from: www.uptodate.com
   Google Scholar
• Négrier S. Temsirolimus in metastatic renal cell carcinoma. Ann Oncol 2008;19(8):1369-70
   PubMed Web of Science ®Google Scholar
• Simpson D, Curran MP. Temsirolimus: in advanced renal cell carcinoma. Drugs 2008;68(5):631-8
   PubMed Web of Science ®Google Scholar
• O'Donnell A, Faivre S, Burris HA 3rd, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1588-95
   PubMed Web of Science ®Google Scholar
• Jac J, Amato RJ, Glessinger S, et al. A phase II study of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma [abstract 5113]. J Clin Oncol 2008;26
   Google Scholar
• Motzer RJ, Escudier BJ, Oudard S, et al. RAD001 plus best supportive care (BSC) vs BSC plus placebo in patients with metastatic renal cell carcinoma (RCC) that has progressed on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase III study (ASCO 2008 Abstract). J Clin Oncol 2008;26:256s
   Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
   PubMed Web of Science ®Google Scholar
• Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26(3):361-7
   PubMed Web of Science ®Google Scholar
• Mita MM, Britten CD, Poplin E, et al. Deforolimus trial 106: a phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669) [abstract 3509]. J Clin Oncol 2008;26
   Web of Science ®Google Scholar
• Malizzia LJ, Hsu A. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin J Oncol Nurs 2008;12(4):639-46
   PubMed Web of Science ®Google Scholar
• Kalaitzidis R, Tsimihodimos V, Bairaktari E, et al. Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis 2005;45(5):851-8
   PubMed Web of Science ®Google Scholar
• Baker SB, Worthley LI. The essentials of calcium, magnesium and phosphate metabolism: part II. Disorders. Crit Care Resusc 2002;4(4):307-15
   PubMedGoogle Scholar
• Bugg NC, Jones JA. Hypophosphataemia: pathophysiology, effects and management on the intensive care unit. Anaesthesia 1998;53(9):895-902
   PubMed Web of Science ®Google Scholar
• Davis SV, Olichwier KK, Chakko SC. Reversible depression of myocardial performance in hypophosphatemia. Am J Med Sci 1988;295(3):183-7
   PubMed Web of Science ®Google Scholar
• Venditti FJ, Marotta C, Panezai FR, et al. Hypophosphatemia and cardiac arrhythmias. Miner Electrolyte Metab 1987;13(1):19-25
   PubMedGoogle Scholar
• Dwyer K, Barone JE, Rogers JF. Severe hypophosphatemia in postoperative patients. Nutr Clin Pract 1992;7(6):279-83
   PubMedGoogle Scholar
• Fischer P, Patel P, Carducci MA, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma [abstract 16020]. J Clin Oncol 2008;26
   PubMedGoogle Scholar
• Whorf RC, Hainsworth JD, Spigel DR, et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC) [abstract 5010]. J Clin Oncol 2008;26
   Google Scholar
• Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008;113(3):508-14
   PubMed Web of Science ®Google Scholar
• Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23(23):5314-22
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007;2(11):1036-41
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005;104(5):1045-8
   PubMed Web of Science ®Google Scholar
• Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23(4):357-61
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26(26):4311-8
   PubMed Web of Science ®Google Scholar
• Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas: update of phase II trial [abstract 10076]. J Clin Oncol 2007;25
   Google Scholar
• Rizzieri DA, Feldman E, Dipersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008;14(9):2756-62
   PubMed Web of Science ®Google Scholar